Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
09 nov. 2021 16h01 HE
|
Avalo Therapeutics
Topline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021Multiple data readouts across programs anticipated within the next six...
Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
13 oct. 2021 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
20 sept. 2021 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
17 sept. 2021 09h11 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
14 sept. 2021 22h23 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
14 sept. 2021 16h01 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
26 août 2021 07h30 HE
|
Cerecor Inc.
Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates...
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
02 août 2021 16h01 HE
|
Cerecor Inc.
Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including...
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
02 août 2021 07h30 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
26 juil. 2021 16h01 HE
|
Cerecor Inc.
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF...